These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

320 related articles for article (PubMed ID: 20585562)

  • 1. Tetherin restricts productive HIV-1 cell-to-cell transmission.
    Casartelli N; Sourisseau M; Feldmann J; Guivel-Benhassine F; Mallet A; Marcelin AG; Guatelli J; Schwartz O
    PLoS Pathog; 2010 Jun; 6(6):e1000955. PubMed ID: 20585562
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cell-cell spread of human immunodeficiency virus type 1 overcomes tetherin/BST-2-mediated restriction in T cells.
    Jolly C; Booth NJ; Neil SJ
    J Virol; 2010 Dec; 84(23):12185-99. PubMed ID: 20861257
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tetherin restricts direct cell-to-cell infection of HIV-1.
    Kuhl BD; Sloan RD; Donahue DA; Bar-Magen T; Liang C; Wainberg MA
    Retrovirology; 2010 Dec; 7():115. PubMed ID: 21184674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. HIV-1 Vpu Antagonizes CD317/Tetherin by Adaptor Protein-1-Mediated Exclusion from Virus Assembly Sites.
    Pujol FM; Laketa V; Schmidt F; Mukenhirn M; Müller B; Boulant S; Grimm D; Keppler OT; Fackler OT
    J Virol; 2016 Aug; 90(15):6709-6723. PubMed ID: 27170757
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-1 Vpu neutralizes the antiviral factor Tetherin/BST-2 by binding it and directing its beta-TrCP2-dependent degradation.
    Mangeat B; Gers-Huber G; Lehmann M; Zufferey M; Luban J; Piguet V
    PLoS Pathog; 2009 Sep; 5(9):e1000574. PubMed ID: 19730691
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Determinants of tetherin antagonism in the transmembrane domain of the human immunodeficiency virus type 1 Vpu protein.
    Vigan R; Neil SJ
    J Virol; 2010 Dec; 84(24):12958-70. PubMed ID: 20926557
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Direct restriction of virus release and incorporation of the interferon-induced protein BST-2 into HIV-1 particles.
    Fitzpatrick K; Skasko M; Deerinck TJ; Crum J; Ellisman MH; Guatelli J
    PLoS Pathog; 2010 Mar; 6(3):e1000701. PubMed ID: 20221443
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu.
    Neil SJ; Zang T; Bieniasz PD
    Nature; 2008 Jan; 451(7177):425-30. PubMed ID: 18200009
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Expression of HIV-1 Vpu leads to loss of the viral restriction factor CD317/Tetherin from lipid rafts and its enhanced lysosomal degradation.
    Rollason R; Dunstan K; Billcliff PG; Bishop P; Gleeson P; Wise H; Digard P; Banting G
    PLoS One; 2013; 8(9):e75680. PubMed ID: 24086611
    [TBL] [Abstract][Full Text] [Related]  

  • 10. HIV-1 Group P is unable to antagonize human tetherin by Vpu, Env or Nef.
    Sauter D; Hué S; Petit SJ; Plantier JC; Towers GJ; Kirchhoff F; Gupta RK
    Retrovirology; 2011 Dec; 8():103. PubMed ID: 22171785
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antagonism of tetherin restriction of HIV-1 release by Vpu involves binding and sequestration of the restriction factor in a perinuclear compartment.
    Dubé M; Roy BB; Guiot-Guillain P; Binette J; Mercier J; Chiasson A; Cohen EA
    PLoS Pathog; 2010 Apr; 6(4):e1000856. PubMed ID: 20386718
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vpu directs the degradation of the human immunodeficiency virus restriction factor BST-2/Tetherin via a {beta}TrCP-dependent mechanism.
    Douglas JL; Viswanathan K; McCarroll MN; Gustin JK; Früh K; Moses AV
    J Virol; 2009 Aug; 83(16):7931-47. PubMed ID: 19515779
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The RING-CH ligase K5 antagonizes restriction of KSHV and HIV-1 particle release by mediating ubiquitin-dependent endosomal degradation of tetherin.
    Pardieu C; Vigan R; Wilson SJ; Calvi A; Zang T; Bieniasz P; Kellam P; Towers GJ; Neil SJ
    PLoS Pathog; 2010 Apr; 6(4):e1000843. PubMed ID: 20419159
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CAML does not modulate tetherin-mediated restriction of HIV-1 particle release.
    Ali MS; Hammonds J; Ding L; Spearman P
    PLoS One; 2010 Feb; 5(2):e9005. PubMed ID: 20126395
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Antiviral activity of the interferon-induced cellular protein BST-2/tetherin.
    Tokarev A; Skasko M; Fitzpatrick K; Guatelli J
    AIDS Res Hum Retroviruses; 2009 Dec; 25(12):1197-210. PubMed ID: 19929170
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Species-specific activity of SIV Nef and HIV-1 Vpu in overcoming restriction by tetherin/BST2.
    Jia B; Serra-Moreno R; Neidermyer W; Rahmberg A; Mackey J; Fofana IB; Johnson WE; Westmoreland S; Evans DT
    PLoS Pathog; 2009 May; 5(5):e1000429. PubMed ID: 19436700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tetherin/BST-2: Restriction Factor or Immunomodulator?
    Li SX; Barrett BS; Guo K; Santiago ML
    Curr HIV Res; 2016; 14(3):235-46. PubMed ID: 26957198
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mutation of a single residue renders human tetherin resistant to HIV-1 Vpu-mediated depletion.
    Gupta RK; Hué S; Schaller T; Verschoor E; Pillay D; Towers GJ
    PLoS Pathog; 2009 May; 5(5):e1000443. PubMed ID: 19461879
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Analysis of the human immunodeficiency virus type 1 M group Vpu domains involved in antagonizing tetherin.
    Petit SJ; Blondeau C; Towers GJ
    J Gen Virol; 2011 Dec; 92(Pt 12):2937-2948. PubMed ID: 21900423
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The interferon-induced protein BST-2 restricts HIV-1 release and is downregulated from the cell surface by the viral Vpu protein.
    Van Damme N; Goff D; Katsura C; Jorgenson RL; Mitchell R; Johnson MC; Stephens EB; Guatelli J
    Cell Host Microbe; 2008 Apr; 3(4):245-52. PubMed ID: 18342597
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.